About: Antibody dynamics to SARS-CoV-2 in Asymptomatic and Mild COVID-19 patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Antibody dynamics to SARS-CoV-2 in Asymptomatic and Mild COVID-19 patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Antibody dynamics to SARS-CoV-2 in Asymptomatic and Mild COVID-19 patients
Creator	Hou, Hongyan Sun, Ziyong Zhang, Bo Li, Yang Wang, Feng Guo, Shujuan Chen, Hong Qi, Huan Huang, Shenghai Tao, Shengce Fan, Xionglin Jiang, Hewei Lai, Danyun Lei, Qing Lin, Xiaosong Ndzouboukou, Banga Ouyang, Zhuqing Wang, Xuening Yu, Caizheng Zhang, Yandi Xu, Zhaowei Xue, Junbiao Yao, Zhongjie Zhang, Hainan Zheng, Yunxiao
source	MedRxiv
abstract	Humoral immunity in asymptomatic infections with SARS-CoV-2 has not been well established. 63 healthy contacts, 63 asymptomatic individuals, and 51 mild patients were enrolled in this study and screened using nucleic acid testing (NAT) and commercial kits of serum IgM and IgG antibodies against recombinant nucleoprotein (N) and spike (S) proteins of SARS-CoV-2. Asymptomatic and mild patients were classified into at least four types based on NAT and serological tests, especially 81% and 25.4% negative NAT but positive IgM/IgG responses, respectively. Antibody dynamics were further demonstrated by IgM and IgG profile responses to SARS-CoV-2 proteome. IgM antibody responses against S1 were elicited in asymptomatic individuals as early to the seventh day after exposure and peaked on days from 17d to 25d, which might be used as early diagnostic biomarkers. Moreover, asymptomatic individuals evoked weaker S1 specific IgM and neutralizing antibody responses than mild patients. Most importantly, S1 specific IgM/IgG responses and the titers of neutralizing antibody in asymptomatic individuals gradually vanished in two months. Our findings might have important implications for serological survey, public health and immunization strategy.
has issue date	2020-07-11(xsd:dateTime)
bibo:doi	10.1101/2020.07.09.20149633
has license	medrxiv
sha1sum (hex)	82d1bf8d52894bca8f3ef1ced7f7f0c918cbc6f6
schema:url	https://doi.org/10.1101/2020.07.09.20149633
resource representing a document's title	Antibody dynamics to SARS-CoV-2 in Asymptomatic and Mild COVID-19 patients
resource representing a document's body	covid:82d1bf8d52894bca8f3ef1ced7f7f0c918cbc6f6#body_text
is schema:about of	named entity 'mild' named entity 'kits' named entity 'recombinant' named entity 'SARS-CoV-2' named entity 'testing' named entity 'SARS-CoV-2' named entity 'IgG antibodies' named entity 'Antibody' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'nucleoprotein' named entity 'immunity passport' named entity 'IgM' named entity 'countries and territories' named entity 'plasma' named entity 'abscissa' named entity 'SPSS' named entity 'asymptomatic infections' named entity 'asymptomatic' named entity 'symptom' named entity 'SARS-CoV-2' named entity 'proteome' named entity 'assay' named entity 'asymptomatic' named entity 'proteome' named entity 'ORF' named entity 'antibodies' named entity 'IgM' named entity 'IgM' named entity 'asymptomatic infections' named entity 'National Health Commission of China' named entity 'Serum' named entity 'asymptomatic' named entity 'SPSS' named entity 'immunization' named entity 'asymptomatic' named entity 'RT-PCR' named entity 'antibody' named entity 'viral transmission' named entity 'antibodies' named entity 'SARS-CoV-2' named entity 'IgM' named entity 'asymptomatic' named entity 'clinical symptoms' named entity 'RdRp' named entity 'China' named entity 'virus' named entity 'asymptomatic infections' named entity 'NSP4' named entity 'SARS-CoV-2' named entity 'IgM' named entity 'asymptomatic' named entity 'IgM' named entity 'IgG antibodies' named entity 'serum' named entity 'preexisting conditions' named entity 'Wuhan' named entity 'SARS-CoV-2' named entity 'antigens' named entity 'infection' named entity 'Cluster analysis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software